Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest update is out from Neurogene ( (NGNE) ).
Neurogene has updated its corporate presentation, highlighting the progress and future plans for its NGN-401 program for Rett syndrome, which is currently in Phase 1/2 clinical trials. The company is leveraging its proprietary EXACT technology and in-house manufacturing to advance its pipeline and explore market opportunities, positioning itself strategically in the biopharmaceutical sector.
More about Neurogene
Neurogene is a clinical-stage biotech company focused on treating complex neurological diseases using its innovative EXACT technology, which aims to address the limitations of conventional gene therapy. The company emphasizes a diverse pipeline targeting neurological conditions such as Rett syndrome, supported by its in-house AAV manufacturing capabilities.
YTD Price Performance: -14.46%
Average Trading Volume: 396,378
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $410.8M
See more data about NGNE stock on TipRanks’ Stock Analysis page.
